Xellia Pharmaceuticals Officially Opens New Anti-Infective Drug Products Manufacturing Site

The Cleveland, Ohio facility will produce critical anti-infective drug products for US hospitals.

Xellia Pharmaceuticals, a pharmaceutical manufacturer specializing in anti-infective treatments, announced that its manufacturing site in Cleveland, Ohio is now commercially operational. The company has released the first anti-infectives manufactured at the site for distribution to US hospitals.

As part of their vertical integration strategy, Xellia plans to continuously expand the capabilities of this site. For example, in addition to commencing commercial supply, the facility is also preparing ramp-up of its newly installed aseptic bag manufacturing line.

Xellia bought the Cleveland site in 2015 and has significantly renovated it since then. It passed a comprehensive Current Good Manufacturing Practices (CGMP) test by FDA in 2020. The facility currently employs over 300 individuals.

“The release of the first commercial product manufactured at our Cleveland facility is a significant milestone for Xellia,” said Carl-Ake Carlsson, CEO and president of Xellia Pharmaceuticals, in a company press release. “We acquired the site to fulfil an ambition to provide US hospitals and patients with critical care products made locally. We are proud to be producing high quality, key anti-infectives and we look forward to working with more partners who are aligned with Xellia’s purpose to save patient lives.”

Source: Xellia Pharmaceuticals